Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
The ongoing fight by Daiichi Sankyo for compensation from India’s Singh brothers over the company’s disastrous purchase of generic drugs giant Ranbaxy has heated up, with the Japanese firm now accusing the tycoons of not telling the truth about the value of assets meant to serve as security for damages.
India’s Health Minister says a new national health care roadmap marks a “huge milestone” towards fixing the country’s failing medical delivery system. But critics say while the scheme is a step in the right direction, it largely recycles old, unmet goals from years ago and caution that implementation will be key.
India’s Glenmark sees the US FDA clearance of its Phase II plan for a novel formulation for COPD as a milestone in its quest to transform into a more innovation-led company and position itself for future growth.
An association representing international research-based medtech companies says the Indian government’s imposition of stiff price controls on cardiac stents has sown an “atmosphere of fear” in the industry, and it warns that the move could stifle patient access to innovative treatments.
Daiichi Sankyo has chalked up a procedural win in its ongoing court battle for compensation from Indian tycoons Malvinder and Shivinder Singh over the Japanese company’s ill-fated acquisition of Indian generic giant Ranbaxy.
An Indian teenager’s court battle for a new tuberculosis drug that doctors say could save her life has cast a harsh spotlight on the slow rollout of breakthrough medicines to treat the disease in the country, one of the world’s biggest TB hotspots.